Nivolumab or Pembrolizumab Combos in Advanced Kidney Cancer? Nivolumab or Pembrolizumab Combos in Advanced Kidney Cancer?
Immunotherapy combinations based on nivolumab entail lower costs for grade 3/4 adverse events than those using pembrolizumab, a finding that could inform treatment decisions.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Hematology | Immunotherapy | Kidney Cancer | Urology & Nephrology